Skip to main content
Monthly Report

Anesthesiology Research Analysis

January 2026
5 papers selected
775 analyzed

December’s anesthesiology research converged on practice-defining randomized trials, mechanistic breakthroughs, and scalable perioperative strategies. A Nature structural study mapped μ-opioid receptor activation trajectories, while a NEJM trial resolved the ketamine vs etomidate debate for RSI without mortality benefit for ketamine. Large RCT evidence discouraged routine high-PEEP recruitment bundles, and a high-level meta-analysis supported low-dose, short-course corticosteroids in severe pneu

Summary

December’s anesthesiology research converged on practice-defining randomized trials, mechanistic breakthroughs, and scalable perioperative strategies. A Nature structural study mapped μ-opioid receptor activation trajectories, while a NEJM trial resolved the ketamine vs etomidate debate for RSI without mortality benefit for ketamine. Large RCT evidence discouraged routine high-PEEP recruitment bundles, and a high-level meta-analysis supported low-dose, short-course corticosteroids in severe pneumonia/ARDS. Cross-agent arousal circuitry in the dmPAG emerged as a translational target to modulate emergence and EEG dynamics.

Selected Articles

1. Non-equilibrium snapshots of ligand efficacy at the μ-opioid receptor.

85.5
Nature · 2025PMID: 41430437

Time-resolved cryo-EM under non-equilibrium captured μ-opioid receptor–Gαiβγ activation intermediates across partial, full, and super-agonists, linking ligand-specific efficacy to distinct activation trajectories. The work provides a structural framework to rationalize efficacy and signaling bias. These insights can inform design of safer opioid therapeutics with improved analgesia-to-toxicity profiles.

Impact: Mechanistic advance mapping ligand efficacy to MOR activation states, creating a blueprint for biased agonist development and safer analgesics.

Clinical Implications: While not practice-changing today, the structural atlas can guide discovery of opioids with reduced respiratory depression and adverse effects.

Key Findings

  • Time-resolved cryo-EM visualized non-equilibrium MOR–G-protein activation intermediates during GTP loading.
  • Distinct activation trajectories correlated with partial, full, and super-agonist efficacy.
  • Provides a structural framework to design biased agonists with improved safety.

2. The role of the dorsomedial periaqueductal gray glutamatergic neurons in promoting arousal under multiple general anesthetics in mice.

85.5
Anesthesiology · 2025PMID: 41396731

Using in vivo calcium imaging, opto/chemogenetics, and EEG across volatile and IV anesthetics, dmPAG glutamatergic neurons were shown to be suppressed under anesthesia and active during wakefulness. Activation delayed induction, accelerated emergence, and reduced burst-suppression, while inhibition potentiated anesthetic effects. Findings identify a convergent arousal substrate across agents with translational potential for emergence control.

Impact: Identifies a causal arousal node that generalizes across anesthetic classes, enabling future neuromodulation or pharmacologic strategies to optimize emergence and EEG dynamics.

Clinical Implications: Motivates translational work to test dmPAG-targeted neuromodulation and to interpret intraoperative EEG more mechanistically for emergence management.

Key Findings

  • dmPAG glutamatergic neurons are suppressed during anesthesia and active in wakefulness across multiple agents.
  • Optogenetic activation prolonged induction and shortened emergence under sevoflurane; burst-suppression ratio decreased.
  • Chemogenetic inhibition enhanced anesthetic effects across agents, supporting a causal arousal role.

3. Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults.

85.5
The New England journal of medicine · 2025PMID: 41369227

A multicenter randomized trial (n=2,365) found no reduction in 28-day in-hospital mortality when ketamine was used instead of etomidate for RSI in critically ill adults. Ketamine was associated with a higher incidence of peri-intubation cardiovascular collapse, while other prespecified safety outcomes were similar. Results provide definitive comparative effectiveness data for induction agent choice.

Impact: Settles a long-standing controversy on RSI induction agents in the critically ill; will influence airway guidelines and hemodynamic management.

Clinical Implications: Do not prefer ketamine over etomidate expecting survival benefit; anticipate higher risk of peri-intubation collapse with ketamine and prepare for aggressive hemodynamic support.

Key Findings

  • No difference in 28-day in-hospital mortality (ketamine 28.1% vs etomidate 29.1%).
  • Higher cardiovascular collapse with ketamine during intubation (22.1% vs 17.0%).
  • Other prespecified safety outcomes were similar between groups.

4. Intraoperative Driving Pressure-Guided High PEEP vs Standard Low PEEP for Postoperative Pulmonary Complications.

85.5
JAMA · 2025PMID: 41334859

In a large multicenter RCT (~1,435 open abdominal cases), a driving pressure–guided high PEEP strategy with recruitment maneuvers did not reduce postoperative pulmonary complications versus standard low PEEP. High PEEP increased intraoperative hypotension and vasoactive use; low PEEP saw more transient desaturations. Findings argue against routine use of individualized high-PEEP recruitment bundles.

Impact: Definitive evidence refining intraoperative ventilation protocols toward safer, less hemodynamically harmful strategies.

Clinical Implications: Avoid routine high-PEEP recruitment strategies; prioritize low tidal volume ventilation and individualized PEEP based on hemodynamic tolerance.

Key Findings

  • No reduction in composite pulmonary complications with high PEEP vs low PEEP.
  • High PEEP increased intraoperative hypotension and vasoactive requirements.
  • Low PEEP had more brief desaturation events.

5. Systemic Corticosteroids, Mortality, and Infections in Pneumonia and Acute Respiratory Distress Syndrome: A Systematic Review and Meta-analysis.

82.5
Annals of internal medicine · 2025PMID: 41325621

PRISMA-style synthesis of 20 RCTs (n=3,459) showed that adjunct low-dose, short-course systemic corticosteroids probably reduce short-term mortality in severe non-COVID pneumonia (RR 0.73) and show benefit across ARDS trials, with little to no increase in hospital-acquired infections. Corticosteroids may also reduce secondary shock in severe pneumonia.

Impact: High-level evidence addressing a long-standing question in severe pneumonia/ARDS management with immediate practice and guideline implications.

Clinical Implications: Consider adjunct low-dose, short-course systemic corticosteroids in severe pneumonia/ARDS while maintaining infection surveillance and tailoring to contraindications.

Key Findings

  • Meta-analysis of 20 RCTs (n=3,459) across severe pneumonia (n=15) and ARDS (n=5).
  • Adjunct corticosteroids probably reduce short-term mortality in severe pneumonia (RR 0.73).
  • Little to no increase in hospital-acquired infections; possible reduction in secondary shock.